Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes
Withdrawn
- Conditions
- Dyslipidemia
- Registration Number
- NCT01265836
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment (statin or combination) reaching the LDL-C goals according to the updated 2004 National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines.
- Detailed Description
MC MD
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- 1064
Inclusion Criteria
- Provision of subject informed consent, Female or male aged = 18 years
- Patients eligible for treatment of dyslipidemia with statins, according to the current guidelines NCEP ATPIII about Dyslipidemias and Atherosclerosis Prevention Receiving lipid-lowering drug treatment for at least 15 days.
Exclusion Criteria
- Involvement in the planning and conduct of the study (applies to either AstraZeneca staff or staff at the study site).
- Previous enrolment or randomisation of treatment in the present study
- Participation in a clinical study during the last 90 days
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The number (#) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines. 1 year The percent (%) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines. 1 year
- Secondary Outcome Measures
Name Time Method The number of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets 1 year The number of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 1 year The number of the secondary event rate cardiovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 year 1 year The percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets 1 year The percent of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 1 year The percent of the secondary event rate cardiovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 year 1 year